Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810446 | 0.86 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL19194617 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL16953747 | 0.82 | HPGD (0.42) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL16954176 | 0.82 | ALDH1A1 (0.56) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL177142 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL21059444 | 0.81 | TSHR (0.46) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL21059443 | 0.81 | TSHR (0.46) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL6935704 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL13257964 | 0.80 | P2RX3 (0.39) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL129594 | 0.79 | AMY1A (0.51) | ALDH1A1LMNAMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115095-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115095-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115095-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2014-11-27 | — | — | US | disclosed |
| EP-2803658-A1 | Phosphinate ruthenium complexes | IDENIX Pharmaceuticals, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-1827688-B1 | NOVEL METATHESIS RUTHENIUM CATALYST | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8765966-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2007117221-A1 | CATALYSTS FOR RING CLOSING METATHESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-10-18 | — | — | WO | disclosed |
| US-7204997-B2 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2007-04-17 | — | — | US | disclosed |
| US-20050158580-A1 | Organic electro luminescent display device | ITO MASATO (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1478403-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA, INC. (CA) | 2004-11-24 | — | — | EP | disclosed |
| US-20030152623-A1 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2003-08-14 | — | — | US | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | ALDH1A1 3489/4885LMNA 4670/4885MAPT 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.